News Details

Jul 27, 2020
Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China    read more...
Jul 21, 2020
Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection    read more...
Jul 17, 2020
BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China    read more...
Jul 15, 2020
BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering    read more...
Jul 12, 2020
BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering    read more...
Jul 02, 2020
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research    read more...
Jul 01, 2020
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China    read more...
Jul 01, 2020
BeiGene Announces Appointment of Angus Grant as Chief Business Executive    read more...
Jun 30, 2020
BeiGene Begins Commercializing XGEVA® (Denosumab) in China    read more...
Jun 23, 2020
BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial    read more...
Jun 19, 2020
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China    read more...
Jun 18, 2020
BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia    read more...
Jun 12, 2020
BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress    read more...
Jun 05, 2020
BeiGene to Present at the Goldman Sachs 41st Annual Global Healthcare Conference    read more...
Jun 03, 2020
BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma    read more...
May 29, 2020
BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program    read more...
May 29, 2020
BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program    read more...
May 27, 2020
Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab    read more...
May 26, 2020
BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program    read more...
May 21, 2020
BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA™ (zanubrutinib) in Israel    read more...